Agile therapeutics inc (AGRX)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Sep'13Jun'13
Operating expenses:
Research and development

10,141

9,858

8,876

8,064

8,698

9,777

10,656

12,282

13,667

14,428

17,208

18,944

20,723

20,929

22,329

24,580

25,171

25,622

23,685

21,125

17,348

13,365

10,785

8,608

0

0

0

General and administrative

11,627

9,000

7,300

6,929

7,479

8,739

10,425

12,184

13,064

12,383

11,424

10,078

9,144

8,792

8,749

8,372

7,921

7,467

6,761

6,404

5,695

5,150

4,527

3,903

0

0

0

Charges

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total operating expenses

21,768

18,858

16,480

15,596

17,196

19,535

21,796

24,882

26,731

26,811

28,632

29,022

29,867

29,721

31,078

32,952

33,092

33,089

30,446

27,530

23,044

18,515

15,312

12,512

0

0

0

Loss from operations

-21,768

-18,858

-16,480

-15,596

-17,196

-19,535

-21,796

-24,882

-26,731

-26,811

-28,632

-29,022

-29,867

-29,721

-31,078

-32,952

-33,092

-33,089

-30,446

-27,530

-23,044

-18,515

-15,312

-12,512

0

0

0

Other income (expense)
Interest income

346

252

245

269

307

366

385

372

332

282

220

175

147

117

85

53

21

5

4

4

3

3

1

0

0

0

0

Interest expense

0

-

-

-

-

1,116

1,365

1,556

1,740

1,918

2,075

2,400

2,444

2,446

2,434

2,201

2,200

2,077

1,915

1,756

1,612

1,566

1,551

1,538

0

0

0

Change in fair value of warrants

-

-

-

-

-

-

0

-70

-41

-

-147

-205

-150

-234

-15

-81

-184

110

-113

-95

-234

-348

-287

-207

0

0

0

Loss on extinguishment of debt

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-1,036

0

0

0

-

-

-

-

-

-

Total other income (expense), net

-52

252

85

-159

-419

-721

-890

-1,114

-1,367

-1,493

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss before benefit from income taxes

-21,820

-18,606

-16,395

-15,755

-17,615

-20,256

-22,686

-25,996

-28,098

-28,304

-30,340

-31,042

-32,014

-31,816

-33,412

-35,019

-35,087

-36,307

-32,788

-27,095

0

-

0

0

-

-

-

Loss before benefit from income taxes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Benefit from income taxes

-

-

-

-

-

-477

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-3,653

0

0

0

-

-

Net loss

-21,820

-18,606

-16,395

-15,755

-17,615

-19,779

-22,209

-25,519

-27,621

-28,304

0

0

0

-

-

-

-

-

-

-

-

-

-

-

0

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-27,440

-29,047

-29,115

-

-32,788

-27,095

0

-

0

0

-

0

0

Net loss per share (basic and diluted) (in dollars per share)

-0.10

-0.09

-0.08

-0.08

-0.13

-0.11

-0.11

-0.16

-0.20

-0.17

-0.22

-0.26

-0.26

-0.19

-0.27

-0.29

-0.27

-0.18

-0.42

-0.38

-0.40

-

-0.34

-0.46

-

-71.67

-70.29

Weighted-average common shares (basic and diluted) (in shares)

76,652

63,035

53,609

43,776

37,308

34,379

34,377

34,277

34,229

34,254

31,937

28,802

28,769

28,768

28,754

28,744

26,826

22,310

22,272

22,202

21,282

-

18,592

8,000

-

51

51

Net (loss) income per share (basic)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.10

-

-

Net (loss) income per share (diluted)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.01

-

-

Weighted-average shares outstanding (basic)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

106

-

-

Weighted-average shares outstanding (diluted)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

822

-

-